Catalyst Pharmaceuticals
Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal
June 20, 2023Medical Communications Catalyst Pharmaceuticals, Rare Diseases, Vamorolone, licence and collaboration, santhera
Swiss specialty pharmaceutical company Santhera and US-based biopharmaceutical company Catalyst Pharmaceuticals have announced that they have signed an exclusive license …
Lawsuit against FDA claims Bernie Sanders played role in approval of rival drug
February 17, 2020Research and Development, Sales and Marketing Bernie, Bernie Sanders, Catalyst Pharmaceuticals, FDA, TRUMP FDA, US FDA
Catalyst Pharmaceutical is attempting to show in court that pressure from US Senator Bernie Sanders led to the approval of …
Catalyst’s lead candidate Firdapse falls short in Congenital Myasthenic Syndromes
October 31, 2019Research and Development Catalyst Pharmaceuticals, FDA, firdapse, pharma, trial failure
Catalyst Pharmaceuticals has made it known that its lead product Firdapse (Amifampridine Phosphate) fell short of its primary endpoint in …
Sanders calls on Catalyst pharma to justify $375,000 price tag for rare disease drug which was once free
February 5, 2019Manufacturing and Production Catalyst Pharmaceuticals, Jacobus Pharmaceuticals, Sanders, USA, pharma, pricing
Shares in Catalyst Pharmaceuticals plummeted Monday, after US Senator Bernie Sanders sent the firm a letter asking them to justify …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
